These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 26549336

  • 1. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M, Oldhoff JM, Klemans RJ, Lahey-de Boer A, de Bruin-Weller MS, Röckmann H, Sanders C, Bruijnzeel-Koomen CA, Pasmans SG, Knulst AC.
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [Abstract] [Full Text] [Related]

  • 2. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A, Yogev A, Confino-Cohen R.
    Int Arch Allergy Immunol; 2011 Nov; 156(1):90-8. PubMed ID: 21447964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, Oude Elberink JN.
    Cochrane Database Syst Rev; 2012 Oct 17; 10(10):CD008838. PubMed ID: 23076950
    [Abstract] [Full Text] [Related]

  • 9. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
    Bilò MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, Campodonico P, Milani M.
    Ann Allergy Asthma Immunol; 2009 Jul 17; 103(1):57-61. PubMed ID: 19663128
    [Abstract] [Full Text] [Related]

  • 10. Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients.
    Vos BJPR, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG.
    J Allergy Clin Immunol Pract; 2017 Jul 17; 5(5):1264-1271. PubMed ID: 28499778
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
    Pospischil IM, Kagerer M, Cozzio A, Angelova-Fischer I, Guenova E, Ballmer-Weber B, Hoetzenecker W.
    Int Arch Allergy Immunol; 2020 Jul 17; 181(10):783-789. PubMed ID: 32781451
    [Abstract] [Full Text] [Related]

  • 12. Pre-emptive Evaluation of Venom Allergy in a Patient with Systemic Mastocytosis.
    Gülen T, Akin C.
    Acta Derm Venereol; 2018 Jan 12; 98(1):149-150. PubMed ID: 28902950
    [No Abstract] [Full Text] [Related]

  • 13. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P.
    J Investig Allergol Clin Immunol; 2006 Jan 12; 16(2):79-85. PubMed ID: 16689180
    [Abstract] [Full Text] [Related]

  • 14. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.
    Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, Franchini M, Reccardini F, Costantino MT, Roncallo C, Mauro M, Boni E, Rizzini FL, Bilò MB, Marcarelli AR, Passalacqua G.
    J Allergy Clin Immunol Pract; 2018 Jan 12; 6(4):1368-1372. PubMed ID: 29258788
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
    Kontou-Fili K, Pitsios C, Kompoti E, Giannakopoulos D, Kouridakis S.
    Int Arch Allergy Immunol; 2018 Jan 12; 176(1):39-43. PubMed ID: 29649812
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of hymenoptera venom immunotherapy.
    Kayikci H, Bostan OC, Tuncay G, Cihanbeylerden M, Damadoglu E, Karakaya G, Kalyoncu AF.
    Allergy Asthma Proc; 2024 Jul 01; 45(4):268-275. PubMed ID: 38982604
    [Abstract] [Full Text] [Related]

  • 17. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
    Selcuk A, Baysan A, Yesillik S, Demirel F, Kartal O, Gulec M, Musabak U, Sener O.
    Ann Med; 2022 Dec 01; 54(1):2321-2325. PubMed ID: 36111408
    [Abstract] [Full Text] [Related]

  • 18. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
    Kalogeromitros D, Makris M, Koti I, Chliva C, Mellios A, Avgerinou G, Theoharides TC.
    Allergol Immunopathol (Madr); 2010 Dec 01; 38(2):69-73. PubMed ID: 19853357
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of venom immunotherapy.
    Hafner T, DuBuske L, Kosnik M.
    Ann Allergy Asthma Immunol; 2008 Feb 01; 100(2):162-5. PubMed ID: 18320918
    [Abstract] [Full Text] [Related]

  • 20. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
    Goldberg A, Confino-Cohen R.
    Ann Allergy Asthma Immunol; 2003 Oct 01; 91(4):405-10. PubMed ID: 14582821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.